The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 18, 2014

Filed:

Jun. 21, 2012
Applicants:

Bing-yan Zhu, Palo Alto, CA (US);

Michael Siu, Burlingame, CA (US);

Steven R. Magnuson, Dublin, CA (US);

Richard Pastor, San Francisco, CA (US);

He Haiying, Shanghai, CN;

Xiao Yisong, Shanghai, CN;

Zheng Jifu, Shanghai, CN;

Xu Xing, Chengdu, CN;

Zhao Junping, Yan'an, CN;

Wendy Liu, Foster City, CA (US);

Inventors:

Bing-Yan Zhu, Palo Alto, CA (US);

Michael Siu, Burlingame, CA (US);

Steven R. Magnuson, Dublin, CA (US);

Richard Pastor, San Francisco, CA (US);

He Haiying, Shanghai, CN;

Xiao Yisong, Shanghai, CN;

Zheng Jifu, Shanghai, CN;

Xu Xing, Chengdu, CN;

Zhao Junping, Yan'an, CN;

Wendy Liu, Foster City, CA (US);

Assignee:

Genentech, Inc., South San Francisco, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5377 (2006.01); A61K 31/454 (2006.01); A61K 31/497 (2006.01); A61K 31/4196 (2006.01); A61K 31/4439 (2006.01); A61K 31/496 (2006.01); C07D 211/00 (2006.01); C07D 413/02 (2006.01); C07D 403/02 (2006.01); C07D 249/08 (2006.01); C07D 401/02 (2006.01); C07D 471/04 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01);
Abstract

A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R, R, R, Rand Rare defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.


Find Patent Forward Citations

Loading…